MedPath

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
Registration Number
NCT00036101
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with acute symptoms of Bipolar Disorder

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Local Institution

🇺🇸

Bellevue, Washington, United States

Local Institution
🇺🇸Bellevue, Washington, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.